PeptiDream (4587) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
1 Nov, 2026Executive summary
FY2023 revenue rose 6.9% to ¥28,712M; core operating profit fell 25.6% to ¥7,166M and profit attributable to owners fell 59.8% to ¥3,036M.
Radiopharmaceutical growth offset lower Drug Discovery and Development revenue; core operating profit, operating profit and net income exceeded forecasts.
Financial highlights
Revenue was ¥28,712M; gross profit was ¥17,219M versus ¥18,113M in FY2022.
Core operating profit was ¥7,166M and IFRS operating profit ¥6,773M; operating profit declined 24.6% YoY.
Profit before tax fell 34.6% to ¥4,353M; profit attributable to owners fell 59.8% to ¥3,036M, and basic EPS was ¥23.41 versus ¥58.19.
Comprehensive income reached ¥8,761M, including ¥5,741M in gains on financial assets at fair value through OCI, including increased RayzeBio share value after BMS’s tender offer announcement.
Outlook and guidance
FY2024 forecast: revenue ¥35,000M, core operating profit ¥10,900M, operating profit ¥10,500M, pretax profit ¥10,200M and parent-attributable profit ¥7,300M.
Growth priorities include marketed products and Alzheimer’s PET imaging, plus RI-PDC program progress and clinical-stage pipeline expansion.
Medium- to long-term revenue targets are ¥35B within ~3 years and ¥50B–¥100B over 5–7 years through a platform-plus-portfolio model.
Latest events from PeptiDream
- Revenue grew 15.3% as losses narrowed; FY2026 operating-profit guidance remains ¥4.6 billion.4587
Q3 2026 - Six new clinical programs and 30% PET revenue growth drive improved H1 2026 results.4587
Q2 2026 - Clinical pipeline expansion, new modalities, and AI-driven efficiency fuel growth and innovation.4587
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue rose 12.6% and net loss narrowed, with strong FY2026 growth forecast.4587
Q1 2026 - FY2025 revenue fell 60% to ¥18.5B; FY2026 targets ¥32B and 6–12 new clinical programs.4587
Q4 2025 - Radiopharmaceutical and peptide pipeline advances, plus facility investments, fuel strong growth.4587
Status Update - Late-stage radiopharma pipeline and AI-driven discovery fuel growth and global partnerships.4587
Investor Day 2024 - Record H1 2024 profit and revenue driven by Drug Discovery and Novartis deal expansion.4587
Q2 2024 - FY2024 saw record revenue and profit growth, robust pipeline, and strong guidance for FY2025.4587
Q4 2024